Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,372 across all filing types
Latest filing 2023-06-30 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 1% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2023-06-30 English
Bonus Issue for the Year Ended 31 December 2022(Update)
Regulatory Filings
2023-06-30 English
Special Dividend for the Year Ended 31 December 2022(Update)
Regulatory Filings
2023-06-30 English
Final Dividend for the Year Ended 31 December 2022(Update)
Regulatory Filings
2023-06-30 English
VOLUNTARY ANNOUNCEMENT - CSTONE PRESENTS RESULTS FROM PHASE 3 STUDY OF SUGEMALIMAB IN FIRST-LINE ESOPHAGEAL SQUAMOUS CELL CARCINOMA AT ESMO GI 2023
Regulatory Filings
2023-06-30 English
VOLUNTARY ANNOUNCEMENT - CSTONE ANNOUNCES GAVRETO (PRALSETINIB) SNDA APPROVAL BY CHINA NMPA FOR FIRST-LINE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL
Regulatory Filings
2023-06-27 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.